Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Lines Up Rival To Teva’s Austedo – But Not Until 2033

Israeli Firm Continues To Fight Aurobindo After Seeing Off Apotex IPR Petition

Executive Summary

Lupin will be able to launch a deutetrabenazine generic rival to Teva’s Austedo brand in the US from 2033, following a settlement agreement between the two firms. However, Aurobindo is continuing to fight a patent-infringement suit with the Israeli firm.

You may also be interested in...



As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline

Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.

Glenmark Builds US OTC Lineup In Wockhardt Deal

Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.

Confusion Persists Over US Biosimilar Interchangeability

The US biosimilars industry is being constrained by misunderstandings stemming from the country’s interchangeability designation, a new paper in BioDrugs has highlighted, citing an urgent need for clarity over the misperception that interchangeable biosimilars are superior to biosimilars without the designation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel